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Abstract 
Microabstract 
Our group reported that nadir testosterone< 20 ng/dL was the 
most significant prognostic factor for overall survival (OS) 
among Japanese patients treated with ADT. Both nadir 
testosterone (<20 ng/dL; p=0.026) and testosterone reduction 
(≥480 ng/dL;p=0.030) as key prognostic factors for primary 
androgen-deprivation therapy in advanced Japanese prostate 
cancer. 
 
 
Purpose: Reductions in testosterone concentration play a 
significant role in the treatment of prostate cancer. Here we 
studied the role of testosterone as a prognostic marker for 
advanced prostate cancer (Stage C) treated with primary 
androgen-deprivation therapy. 
Patients and Methods: A total of 348 patients were treated using 
androgen-deprivation therapy as first-line therapy for prostate 
cancer at Chiba University hospital between 1999 and 2016. Of 
these, 222 patients with advanced prostate cancer (Stage C) were 
enrolled in this study. The prognostic values of serum 
testosterone level and other clinical factors were evaluated in 
association with prostate-specific antigen progression-free 
survival during first-line therapy and overall survival. 
Results: Median age was 73 years. Prostate-specific antigen at 
baseline was 86 ng/ml. Gleason score 6/7/8/9 was seen in 2.3%, 
19.4%, 21.2%, and 41.9%, respectively. Mean follow-up was 60.5 
months. Median testosterone at baseline was 482 ng/dl and nadir 
testosterone was 13 ng/dl. No variable associated with 
testosterone predicted progression-free survival. With regard 
to overall survival, multivariate analysis identified nadir 
testosterone 20 ng/dl (hazard ratio=0.44, p=0.026) and 
testosterone reduction 480 ng/dL (hazard ratio=0.35, p=0.030) 
as independent prognostic factors. 
With regard to progression-free survival, multivariate analysis 
identified nadir prostate-
ratio=3.07, p<0.001), presence of lymph node metastasis (hazard 
ratio=1.67, p=0.017) and time to nadir prostate-specific antigen 
(hazard ratio=0.30, p<0.001) as independent prognostic factors. 
Conclusion: Our data suggested both nadir testosterone (<20 
ng/dL; p=0.026) and testosterone reduction (≥480 ng/dL; 
p=0.030) as key prognostic factors for primary androgen-
deprivation therapy in advanced Japanese prostate cancer. 
 
 
Clinical Practice Points 
The incidence of prostate cancer has recently been increasing 
rapidly in Japan. Most patients with advanced prostate cancer 
respond to ADT temporarily, but subsequently progress to 
castration-resistant prostate cancer. According to current 
guidelines, the target testosterone level during ADT for 
prostate cancer is < 50 ng/dL. Our group reported that nadir 
testosterone < 20 ng/dL was the most significant prognostic 
factor for overall survival (OS) among Japanese patients treated 
with ADT. 
Our data suggested both nadir testosterone (<20 ng/dL; p=0.026) 
and testosterone reduction (≥480 ng/dL; p=0.030) as key 
prognostic factors for primary androgen-deprivation therapy in 
advanced Japanese prostate cancer. Based on the two independent 
prognostic factors (testosterone reduction ≥480 ng/dL and nadir 
testosterone<20 ng/dL) identified in this study, we attempted to 
divide patients into 3 groups: poor risk group (neither status 
achieved); intermediate group (one of the two statuses 
achieved); and favorable risk group (both statuses achieved). 
The Kaplan-Meier curve showed significant differences in 
prognosis between groups. Only the intermediate and poor risk 
groups showed marginal differences (p=0.067). Based on these two 
key factors, we may consider the treatment strategy in advanced 
prostate cancer patients. 
Our data thus indicated the clinical significance of monitoring 
shifts in testosterone reductions during ADT. Furthermore, 
consideration of treatment strategies based on testosterone 
reduction and nadir testosterone may be warranted in prostate 
cancer patients treated with primary ADT. 
 
Key words: prostate cancer, testosterone, prostate-specific 
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Introduction 
The incidence of prostate cancer has recently been increasing 
rapidly in Japan1. For patients with advanced prostate cancer, 
androgen-deprivation therapy (ADT) has served as the main 
therapy, using nonsteroidal antiandrogens combined with a 
luteinizing hormone-releasing hormone analogue. Most patients 
with advanced prostate cancer respond to ADT temporarily, but 
subsequently progress to castration-resistant prostate cancer. 
According to current guidelines, the target testosterone level 
during ADT for prostate cancer is < 50 ng/dL2. This level was 
defined more than 40 years ago, when testosterone tests were 
limited, and was not supported by clinical evidence. Van et al. 
reported that medically castrated men achieved significantly 
lower testosterone levels than those surgically castrated3. Our 
group reported that nadir testosterone < 20 ng/dL was the most 
significant prognostic factor for overall survival (OS) among 
Japanese patients treated with ADT4. Klotz et al. also described 
the clinical significance of achieving a nadir testosterone < 20 
ng/dL within the first year of ADT5,6. 
A key limitation of previous evidence was that all analyses 
assessing the clinical significance of nadir testosterone < 20 
ng/dL were based on patients of various backgrounds, including 
differences in localized and metastatic disease (stage A-D) 4. 
Results obtained previously were thus not necessarily 
appropriate for patients treated with primary ADT. Considering 
that curative treatment represents the first choice for 
localized prostate cancer, analysis of ADT patients with 
advanced-stage prostate cancer is essential. 
  Since serum testosterone plays a significant role in prostate 
cancer, the present study investigated the role of testosterone 
reduction as a prognostic marker in advanced prostate cancer 
patients treated with primary ADT. 
 
 
 
Patients and Methods 
Patient selection and clinical variables 
We retrospectively reviewed 348 prostate cancer patients treated 
with primary ADT at Chiba University Hospital from 1999 to 2015 
and selected all 222 patients with advanced prostate cancer with 
clinical T3(Stage C). Disease was clinically staged according to 
the 1997 TNM classification. Bone metastasis was assessed by 
computed tomography (CT) and bone scintigraphy. 
The prognostic values of serum testosterone level and other 
clinical factors were evaluated in association with PSA 
progression-free survival (PFS) during first-line therapy and 
OS. Patients treated with radiation or radical prostatectomy as 
first-line therapy, or with a history of radiation to the 
pelvis, systemic chemotherapy, or use of 5-alpha-reductase 
inhibitors were excluded. 
Variables included in analysis were age, body mass index, 
clinical T stage, lymph node metastasis, bone metastasis, 
visceral metastasis, Gleason score, high volume(defined as 
presence of visceral metastases or ≥4 bone lesions with ≥1 
beyond the vertebral bodies and pelvis 7, baseline PSA, nadir 
PSA, Alkaline phosphatase (ALP),time to nadir PSA, baseline 
testosterone, nadir testosterone, testosterone reduction and 
time to nadir testosterone. 
The Architect Testosterone II® (Abbot Diagnostics, Lake 
Forest, IL) was used to determine serum testosterone levels. 
Normal levels as defined by the laboratory were 142-923 ng/dL in 
men. 
 
Compliance with ethical standards 
The current study is approved by institutional review board with 
approved number of 2252. 
 
 Definition of PSA progression 
In this study, PSA failure was defined either using the 
definition of the Prostate Cancer Clinical Trials Working Group 
2 as a rising PSA greater than 2 ng/mL higher than the nadir, 
25% over the nadir, and confirmed by a second PSA 3 weeks later, 
or when the patient’s physician decided to stop treatment 
because of increased PSA. In addition, the patient was required 
to show a castrated level of testosterone (< 50ng/dL). 
 
 
Statistical analysis 
Cox proportional hazards modeling was used to perform uni- and 
multivariate analyses. The Kaplan-Meier method was used for 
statistical analyses. We derived relative risks and 95% 
confidence intervals (95%CIs). Student’s t-test, the chi-square 
test, and Wilcoxon’s signed rank test were used to assess 
associations of nadir testosterone <20 ng/dL with other clinical 
variables. Statistical computations were carried out using JMP 
version 12.0.0 (SAS Institute, Cary, NC). Two-sided values of 
p<0.05 were considered statistically significant. 
 
 
Results 
Table 1 lists the characteristics of the 222 patients enrolled 
in this study. Mean duration of follow-up was 60.5 months. 
Median age was 73 years (range, 48-91 years). Median PSA 
concentration was 86.03 ng/mL (range: 3.23-7366 ng/mL) at the 
time of prostate cancer diagnosis. The rate of clinical stage T3 
was 88.8%. Lymph node metastasis, bone metastasis and visceral 
metastasis were seen in 39.2%, 50.9% and 7.7%, respectively. The 
frequency of high-volume patients was 26.1%. Gleason scores 
6/7/8/9 were 2.3%, 19.4%, 21.2% and 41.9%. Of the 222 patients, 
98.2% were initially treated with combined androgen blockade 
(CAB). The frequency of CAB was 98.2% and of the patients who 
received LHRH, 61.2% were using leuprolide acetate, 25.1% were 
using goserelin acetate, and 9.6% were using degarelix acetate. 
The frequency of patients who underwent surgical castration was 
3.7%.Systemic chemotherapy (docetaxel) was administered to 17.6% 
of patients after several courses of ADT. Median nadir PSA was 
0.12 ng/mL. Median nadir testosterone level attained during ADT 
was 13 ng/dL. Median time to nadir testosterone was 375 days. 
Median testosterone reduction was 455 ng/dL. 
Table 2 shows the results of uni- and multivariate analyses 
for PFS. On univariate analysis, age (p=0.025), lymph node 
metastasis (p<0.0001), bone metastasis (p<0.0001), high volume 
(p<0.0001), Gleason score ≥9 (p<0.0001), baseline PSA 
(p<0.0001), ALP (p<0.0001), nadir PSA (p<0.0001), and time to 
nadir PSA (p<0.0001) were significantly associated with PFS. In 
multivariate analysis, nadir PSA (p=0.001), time to nadir PSA 
(p=0.001) and presence of bone metastasis (p=0.003) were 
identified as independent prognostic factors. 
The associations of nadir PSA, time to PSA nadir, lymph node 
metastasis and Kalan-Meier analysis also showed significant 
differences for PFS (nadir PSA, p<0.001;time to nadir PSA, 
p<0.001; bone metastasis, p<0.001) (Fig. 1a-c). 
Table 3 shows the results of uni- and multivariate analyses 
for OS. On univariate analysis, lymph node metastasis (p=0.017), 
bone metastasis (p=0.005), high volume (p=0.001), Gleason score 
(p<0.0001), ALP (p=0.005), nadir PSA (p=0.0001), time to PSA 
nadir (p=0.001), nadir TST (p=0.002) and TST reduction (p=0.038) 
were significantly associated with OS. On multivariate analysis, 
nadir testosterone (p=0.026) and testosterone reduction 
(p=0.030) were significantly associated with OS. The 
associations of nadir testosterone, testosterone reduction and 
OS were also examined using the Kaplan-Meier method, and showed 
significant differences for OS (testosterone reduction 480 
ng/dL, p=0.0039; nadir testosterone < 20 ng/dL, p=0.0003) (Fig. 
2a, b). 
Based on these two factors, patients were divided into three 
groups: the Favorable group was defined as patients with nadir 
testosterone <20 ng/dL and testosterone reduction ≥480 ng/dL; 
the Intermediate group was defined as patients with nadir 
testosterone <20 ng/dL or testosterone reduction ≥480 ng/dL; and 
the Poor group was defined as patients with nadir testosterone 
20 ng/dL and testosterone reduction <480 ng/dL. Associations 
between group status and OS were examined using the Kaplan-Meier 
method, and showed significant differences(Favorable vs 
Intermediate, p=0.025; Favorable vs Poor, p=0.0025; Intermediate 
vs Poor, p=0.067). 
To assess the clinical characteristics related to testosterone 
reduction, two groups (testosterone reduction <480 ng/dL vs 
testosterone reduction ≥480 ng/dL) were compared (Table 4). 
Testosterone reduction <480 ng/dL group showed significantly 
lower Gleason score and higher baseline testosterone (p=0.029 
and p<0.001, respectively). 
To assess the clinical characteristics related to nadir 
testosterone, two groups (nadir testosterone <20 ng/dL vs. nadir 
testosterone ≥20 ng/dL) were also compared in terms of various 
clinical factors (Table 5). Nadir testosterone <20 ng/dL groups 
showed significantly lower clinical T stage and longer time to 
testosterone nadir (p=0.020, p=0.0025, respectively). The 
baseline characteristic difference related to testosterone 
reduction ≥480 ng/dL and nadir testosterone <20 ng/dL confirmed 
the independence of these two prognostic factors. 
To assess the clinical significance of the speed of 
testosterone reduction, patients were divided into two groups. 
The rapid type was defined as <180 days and the slow type was 
defined as ≥180 days based on time to testosterone 20 ng/dL and 
testosterone reduction 480 ng/dL. No significant difference in 
OS was observed between the two types (Fig. 4a, b). The present 
results indicated that the critical factor for prognosis was not 
a rapid decrease in testosterone level, but rather the extent of 
the decrease in testosterone. 
 
 
Discussion 
To the best of our knowledge, the current study is the first 
to identify the clinical significance of serum testosterone 
reduction (≥480 ng/dL) in advanced prostate cancer patients 
treated with primary ADT. Serum nadir testosterone 20 ng/dL was 
also found to be a significant prognostic factor, while Gleason 
score and high-volume tumor did not remain as independent 
prognostic factors. Our data thus indicated the clinical 
significance of monitoring shifts in testosterone reductions 
during ADT. Furthermore, consideration of treatment strategies 
based on testosterone reduction and nadir testosterone may be 
warranted in prostate cancer patients treated with primary ADT. 
Serum testosterone level has been regarded as an important 
factor correlated with other clinical variables in prostate 
cancer. Although no previous studies have discussed the extent 
of testosterone reduction, a number of lines of evidence related 
to basal testosterone level and prognosis have been revealed. In 
the literature, higher pre-treatment testosterone levels have 
been related to lower Gleason score 6-8, lower pathological stage 
9-11, and lower risk of biochemical failure after radical 
prostatectomy 12. High testosterone reductions were related to 
high basal testosterone level and lower Gleason score (Table 4). 
Since basal testosterone level has been related to favorable 
prognosis, we also assessed the prognostic significance of basal 
serum testosterone levels. Basal testosterone level did not show 
any prognostic significance when cut-off was made at the median 
value (480 ng/dL) (Tables 2 and 3). We also studied various cut-
offs for basal testosterone level (from 300 to 600 ng/dL), but 
no significant differences were seen with either PFS or OS. 
Furthermore, as shown from the significant difference in 
characteristics of patients achieving nadir testosterone <20 
ng/dL and testosterone reduction ≥480 ng/dL (Tables 4 and 5), no 
correlation was observed between nadir testosterone and 
testosterone reduction (r=-0.0395) (Supplementary figure 
1).These results indicated that testosterone reduction ≥480 
ng/dL represented an independent prognostic factor distinct from 
basal testosterone and nadir testosterone in prostate cancer 
patients treated with primary ADT. 
The importance of monitoring nadir testosterone levels during 
ADT has been emphasized in previous papers 4, 5, 13. Morote et al. 
reported the clinical significance of breakthrough testosterone 
increases over 20 ng/dL in patients with 13.7% of clinical T≥3, 
without distant metastasis. They argued that absence of 
breakthrough is a good predictor for survival free of androgen-
independent progression 13. Klotz et al. reported achieving nadir 
testosterone < 20 ng/dL in the first year of ADT predicted the 
prognosis of patients receiving ADT among patients who relapsed 
after radiotherapy without evidence of distant metastasis5. We 
have also reported the prognostic significance of nadir 
testosterone< 20 ng/dL among 65.2% of patients with clinical T3 
prostate cancer patients who received CAB4. In accordance with 
the previous result, our data also indicated the prognostic 
significance of nadir testosterone <20 ng/dL. However, 
significant differences in patient background were seen between 
previous reports and the current study. Previous studies were 
conducted using data from patients with a wide variety of 
backgrounds, including in terms of localized and metastatic 
disease (stage A-D), while the current study include only 
patients with clinical T ≥3. Since curative treatment is the 
standard therapy for localized cancer, exclusion of localized 
prostate cancer is essential in assessing reliable predictors 
for patients suitable for primary ADT. In this regard, the 
current study is first to identify the clinical significance of 
nadir testosterone < 20 ng/dL in the pure advanced prostate 
cancer population treated with primary ADT. 
Based on the recent LATITUDE and STMPEDE trial, significance 
of testosterone reduction by abiraterone on overall survival in 
metastatic hormone sensitive prostate cancer (HSPC) patients 
were determined with the HR of 0.62 and 0.63, respectively14, 15. 
These data are in accordance with our data that emphasized the 
clinical significance of absolute testosteroneTST reduction in 
metastatic HSPC patients. 
Our data indicated that speed of testosterone reduction was 
not associated with any difference in prognosis. The slow 
reduction group in terms of testosterone reduction ≥480 ng/dL or 
nadir testosterone <20 ng/dL did not show any difference in 
prognosis compared with the rapid reduction group (p=0.762 and 
p=0.525, respectively). This result was in accordance with a 
previous finding that the speed of testosterone reduction to 
nadir testosterone < 20 ng/dL was not associated with any 
difference in prognosis4. 
Based on the two independent prognostic factors (testosterone 
reduction ≥480 ng/dL and nadir testosterone<20 ng/dL) identified 
in this study, we attempted to divide patients into 3 groups: 
poor risk group (neither status achieved); intermediate group 
(one of the two statuses achieved); and favorable risk group 
(both statuses achieved). The Kaplan-Meier curve showed 
significant differences in prognosis between groups. Only the 
intermediate and poor risk groups showed marginal differences 
(p=0.067). Based on these two key factors, we may consider the 
treatment strategy in advanced prostate cancer patients. As 
indicated in the CHAARTED trial, a significant survival benefit 
was clinically identified in patients with high-volume prostate 
cancer treated with ADT plus docetaxel compared with ADT alone 
16. In our analysis, presence of high volume was not an 
independent prognostic factor for OS in patients with advanced 
prostate cancer receiving ADT. Moreover, chemotherapeutic agents 
reduce activities of daily living, especially in elderly or 
frail patients17, 18.Up-front docetaxel may be ideal for high-
volume tumors, but may be difficult in some patients such as 
elderly individuals with low performance status. Based on our 
analysis, that these data generated the hypothesis that low and 
intermediate risk patients by our' criteria may gain less from 
the addition of docetaxel. On the other hand, the poor risk 
group of patients should be considered for early use of 
docetaxel or novel androgen receptor (AR)-targeted drugs. Based 
on these characteristics, treatment strategies may be developed 
by assessing the type of testosterone reduction during first-
line ADT. Further evidence will clarify the precise mechanisms 
by which testosterone is affected by clinical factors. 
  
Several limitations to the present study must be considered. 
First, this study was based on data from only a single institute 
and retrospectively analyzed a limited number of patients. 
Second, the timing of serum testosterone measurements was not 
fixed. 
Testosterone production occurs during the night to early 
morning and gradually decreases during the day19. 
Blood tests were performed by noon, which may have affected 
basal testosterone levels in individual patients. So, the result 
of absolute testosterone reduction may also be affected by the 
timing of the serum testosterone measurement. Therefore, by 
looking at the combination of testosterone reduction and nadir 
testosterone, we may objectively assess the prognosis of 
prostate cancer patients as we proposed in our risk group 
classification. In addition, some reports have described the 
utility of measuring free testosterone rather than total 
testosterone 20. Use of free testosterone as a clinical variable 
in the future may thus be of great interest. 
 
 
Conclusion 
The present study identified testosterone reduction 480 ng/dL 
as a significant prognostic factor in advanced prostate cancer 
patients (Stage C)treated with primary ADT. In combination with 
nadir testosterone <20 ng/dL, this value may help determine 
treatment strategies in patients with advanced prostate cancer. 
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Legends 
Figure 1. a) OS according to testosterone reduction divided by 
reduction <480 ng/dL or 480 ng/dL. Log-rank test p values. b) OS 
according to nadir testosterone divided by nadir testosterone 
-rank test p values. 
 
Figure 2. a) OS according to nadir PSA divided by nadir PSA 
<0.1 ng/ml, or 0.1 ng/ml. Log-rank test p values. b) OS 
according to time to nadir PSA divided by <250 days or 250 days. 
Log-rank test p values. c) OS according to bone metastasis. Log-
rank test p values. 
 
Figure 3. OS according to risk classification. Poor risk was 
defined as testosterone nadir > 20 ng/dL and testosterone 
reduction < 480 ng/dL, intermediate as testosterone nadir > 20 
ng/dL or testosterone reduction < 480 ng/dL, and favorable as 
testosterone nadir < 20 ng/dL and testosterone reduction 480 
ng/dL. Log-rank test p values. 
 
Figure 4. a) OS in rapid-type patients who attained 
testosterone reduction 480 ng/dl before 180 days, and in slow-
type patients who attained testosterone reduction 480 ng/dl 
after 180 days. b) OS in rapid-type patients who attained 
testosterone 20 ng/dl before 180 days, and in slow-type patients 
who attained testosterone 20 ng/dl after 180 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 1. Characteristics of 222 patients
Median/mean follow-up (months) 44.7/60.5
Median/mean age (years) 73/72.1
Median/mean BMI (kg/m
2
) 23.3/23.2
Median/mean alkaline phosphatase (IU/L) 257.5/478.3
Baseline PSA (ng/mL)
   Median/mean 86.0/571.5
   less than 100 115 (51.8)
   100-less than 500 52 (23.4)
   500 or greater 52 (23.4)
Median/mean baseline TST (ng/dL) 482/510
T stage (n)
T1/T2/T3/T4/Tx 3 (1.3) / 10 (4.5) / 156 (70.3) /41 (18.5) /12 (5.4)
Lymph node metastasis (n)
N+ / N- 87 (39.2) /128 (57.7)  
Distant metastasis (n)
Yes / No 126 (56.8) / 91 (41.0)
Bone metastasis (n)
Yes / No 113 (50.9) / 104 (46.8)
Visceral metastases (n)
Yes / No 17 (7.7) / 200 (90.1)
High volume (n)
Yes / No 58 (26.1) / 153 (68.9)
Gleason score (n)
6 or less 5 (2.3)
7 43 (19.4)
8 47 (21.2)
9 or greater 93 (41.9)
No. antiandrogen medication
CAB 218 (98.2)
monotherapy 4 (1.8)
LHRH agonist/antagonist/surgery (n)
Leuprorelin 134 (61.2)
Goserelin 55 (25.1)
Degarelix 21 (9.6)
Surgical castration 8 (3.7)
Systemic docetaxel chemotherapy (n) 39 (17.6)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.
Uni- and multivariate analyses of factors associated with prostate cancer-free survival
Univariate analysis Multivariate analysis
P-value HR (95%CI) P-value HR (95%CI)
Age 73 years 0.010 1.54(1.11-2.17) 0.573 1.12(0.76-1.65)
Body mass index 23.3 kg/m
2 0.857 1.03(0.71-1.51) - -
clinical T stage 3 0.870 1.07(0.51-2.73) - -
Lymph node metastasis <.0001 2.11(1.49-2.97) 0.365 1.20(0.80-1.82)
Bone metastasis <.0001 3.53(2.47-5.10) 0.003 2.11(1.29-3.47)
Visceral metastases 0.059 1.86(0.97-3.24) - -
High volume <.0001 2.77(1.90-3.98) 0.430 1.21(0.75-1.95)
Gleson score 9 <.0001 2.56(1.77-3.72) 0.511 1.16(0.75-1.81)
Baseline PSA 86 ng/ml <.0001 1.92(1.37-2.70) 0.656 1.10(0.70-1.73)
Alkaline phosphatase 257 IU/l <.0001 2.07(1.47-2.95) 0.408 1.18(0.79-1.76)
Nadir PSA 0.1 ng/ml <.0001 4.40(3.06-6.41) <.0001 4.65(3.03-7.25)
Time to PSA nadir 250 days <.0001 0.27(0.18-0.38) <.0001 0.23(0.15-0.35)
Baseline testosterone 480 ng/dL 0.169 0.73(0.46-1.14) - -
Nadir testosterone 20 ng/dL 0.185 1.37(0.85-2.16) - -
Time to testosterone nadir 360 days 0.443 1.18(0.77-1.82) - -
Testosterone reduction 480 ng/dL 0.106 0.64(0.37-1.10) - -
Table 3. 
Uni- and multivariate analyses of factors associated with overall survival
Univariate analysis Multivariate analysis
P-value HR (95%CI) P-value HR (95%CI)
Age 73 years 0.273 0.75 (0.44-1.25) - -
Body mass index 23.3 kg/m
2 0.941 1.02 (0.57-1.84) - -
Clinical T stage 3 0.661 1.35 (0.42-8.28) - -
Lymph node metastasis 0.017 1.86 (1.12-3.12) 0.415 1.27 (0.72-2.26)
Bone metastasis 0.005 2.10 (1.24-3.65) 0.803 1.09 (0.46-2.44)
Visceral metastases 0.397 1.52 (0.53-3.46) - -
High volume 0.001 2.66 (1.54-4.51) 0.149 1.71 (0.83-3.64)
Gleson score 9 <.0001 3.41 (1.93-6.20) 0.187 1.56 (0.80-3.12)
Baseline PSA 86 ng/ml 0.200 1.39 (0.84-2.35) - -
Alkaline phosphatase 257 IU/L 0.005 2.20 (1.27-3.95) 0.215 1.49 (0.79-2.88)
Nadir PSA 0.1 ng/ml 0.001 2.46 (1.43-4.41) 0.327 1.41 (0.71-2.90)
Time to PSA nadir 250 days 0.001 0.42 (0.25-0.71) 0.106 0.59 (0.31-1.11)
Baseline testosterone 480 ng/dL 0.195 0.63 (0.31-1.28) - -
Nadir testosterone 20 ng/dL 0.002 0.34 (0.18-0.67) 0.040 0.47 (0.23-0.96)
Time to testosterone nadir 360 days 0.632 0.85 (0.44-1.68) - -
Testosterone reduction 480 ng/dL 0.023 0.39 (0.15-0.88) 0.041 0.46 (0.24-0.97)
  
 
 
 
 
 
 
Table 4.
Clinical variables and absolute testosterone reduction ³480 ng/dL
<480 ³480 P-value
Age (years) 72/71.9 73/72.3 0.782
†
Body mass index (kg/m
2
) 23.9/23.2 22.7/22.8 0.136
†
cT3 (%) 93.3 97.7 0.280
††
Lymph node metastases (%) 45.0 28.2 0.076
††
Bone metastases (%) 55.0 52.3 0.276
††
Visceral metastases (%) 8.2 4.3 0.416
††
High volume (%) 29.3 22.2 0.415
††
Gleason score ³9 (%) 54.5 32.6 0.029
††
Baseline PSA (ng/mL) 144.8/787.2 71.8/432.3 0.108
†††
Nadir PSA (ng/mL) 0.19/4.06 0.07/1.51 0.196
†††
Time to PSA nadir (days) 266/391 266/427 0.856
†††
Baseline testosterone (ng/dL) 405/387 623/696 <0.001
†††
Nadir testosterone (ng/dL) 14/16 14/14 0.354
†††
Time to testosterone nadir (days) 336/525.1 374/675.9 0.748
†††
† T-test
†† Chi square
††† Wilcoxon
Median/average nadir TST (ng/dL)
Table 5.
Clinical variables and nadir testosterone 20 ng/ml
Less than 20 20 or gretaer P-value
Age 72/72.0 72/71.8 0.932
†
Body mass index (kg/m
2
) 23.4/23.0 23.5/23.4 0.494
†
cT3 (%) 82.9 94.1 0.020
††
Lymph node (%) 45.1 26.8 0.057
††
Bone metastasis (%) 50 63.4 0.161
††
Visceral metastasis (%) 4.9 12.2 0.126
††
High volume (%) 24.5 29.3 0.713
††
Gleson score 9 (%) 39.2 46.3 0.427
††
PSA at baseline (ng/mL) 136/686.2 81.7/598.2 0.392
†††
Nadir PSA (ng/ml) 0.14/2.47 0.22/4.34 0.156
†††
Time to nadir PSA (days) 249/422 210/343 0.348
†††
Testosterone at baseline (ng/dL) 479/530 469/490 0.28
†††
Time to nadir testosterone (days) 428/662 194/348 0.0025
†††
Testosterone reduction (ng/dL) 478/520 439/461 0.107
†††
† T-test
†† Chi square
††† Wilcoxon
Median/Average  Nadir TST (ng/dL)
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